Side Effect Severity Predicted In Head And Neck Cancer Patients By Thermal Imaging To Detect Oral Temperature Changes
Slight temperature increases of the oral mucus membranes early in a head and neck cancer patient's chemotherapy and radiation therapy (chemoradiotherapy) treatment is a predictor of severe mucositis later in treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Mucositis, or mouth sores, is a common side effect of chemoradiotherapy for head and neck cancer that is painful and can be very severe. Physicians cannot predict which patients will have mild mucositis or severe mucositis that would require narcotic pain medication, nutritional support and/or feeding tubes. Researchers in this study hypothesized that using sensitive thermal imaging technology to measure temperature changes of less than one-tenth of a degree early in treatment could predict the severity of mucositis later in treatment.
Independent of other factors, such as smoking history and HPV status, matted lymph nodes appear to signal increased chance of oropharyngeal cancer spreading to other parts of the body Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies. Patients with oropharyngeal squamous cell carcinoma who had "matted" lymph nodes - nodes that are connected together - had a 69 percent survival rate over three years, compared to 94 percent for patients without matted nodes, according to a study published online ahead of print publication in Head & Neck. The oropharynx is an area that includes the back of the tongue, soft palate, throat and tonsils.
From tracking activities within bacteria to creating images of molecules that make up human hair, several experiments have already demonstrated the unique abilities of the revolutionary imaging technique called multi-isotope imaging mass spectometry, or MIMS, developed by researchers at Brigham and Women's Hospital (BWH). MIMS can produce high-resolution, quantitative three-dimensional images of stable isotope tags within subcellular compartments in tissue sections or cells. With its use of stable isotopes as tracers, MIMS has opened the door for biomedical researchers to answer various biological questions, as two new studies have demonstrated. These studies looked at the use of MIMS in tracking cell division in intestinal stem cells, lipid turnover in Drosophila flies, protein turnover in ear cells, and opened the way to human application by detecting the formation of new white blood cells.
Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR inhibitors, such as erlotinib, is critical to personalizing head and neck cancer treatments. In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumors unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient's smoking status.
Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Human papillomavirus, or HPV, has recently been linked to some types of head and neck cancer that are becoming more prominent in the United States, mostly among men. Patients infected with oral HPV type 16 have a 14 times greater risk of developing one of these cancers, which usually form on the tonsils and at the back of the tongue. The correlation between HPV and oral cancer was only established in 2007, so it is not well understood how to detect or prevent these cancers. Researchers sought to understand how prevalent oral HPV is in the U.